Ryvu Therapeutics (WAR:RVU) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:RVU Ryvu Therapeutics SA WAR:RVU
66 GF Score
Price zł14.98
GF Value zł45.84
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Ryvu Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

WAR:RVU vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Ryvu Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ryvu Therapeutics Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Margin of Safety % (DCF FCF Based) falls into.


WAR:RVU
66GF Score
Ryvu Therapeutics SA WAR:RVU
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ryvu Therapeutics (WAR:RVU) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of zł14.98 is trading 67.3% below its estimated GF Value™ of zł45.84. GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.

Key valuation signals for WAR:RVU:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: zł45.84 vs. price of zł14.98 (67.3% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the WAR:RVU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryvu Therapeutics Business Description

Other Exchanges 9Y4:Germany
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score

Get the complete analysis for WAR:RVU

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł14.98
Price
zł45.84
GF Value